HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
manuscript.pdf663.41 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/63714

タイトル: Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer
著者: Furusawa, Jun 著作を一覧する
Homma, Akihiro 著作を一覧する
Onimaru, Rikiya 著作を一覧する
Sakashita, Tomohiro 著作を一覧する
Yoshida, Daisuke 著作を一覧する
Hatakeyama, Hiromitsu 著作を一覧する
Mizumachi, Takatsugu 著作を一覧する
Kano, Satoshi 著作を一覧する
Tsuchiya, Kazuhiko 著作を一覧する
Yasuda, Koichi 著作を一覧する
Shirato, Hiroki 著作を一覧する
Fukuda, Satoshi 著作を一覧する
キーワード: Head and neck cancer
Hypopharyngeal cancer
Intra-arterial
Chemotherapy
Radiotherapy
発行日: 2015年12月
出版者: Elsevier
誌名: Auris nasus larynx
巻: 42
号: 6
開始ページ: 443
終了ページ: 448
出版社 DOI: 10.1016/j.anl.2015.04.003
抄録: Objective: We retrospectively assessed the indications for superselective intra-arterial infusion of cisplatin with concomitant radiotherapy (RADPLAT) in patients with hypopharyngeal cancer (HPC). Methods: Between April 2000 and March 2013,41 previously untreated patients received superselective intra-arterial infusion of cisplatin (100-120 mg/m2 per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional radiotherapy (65-70 Gy). Results: During the median follow-up period of 5.5 years, a statistically significant difference in the 5-year overall survival was noted between patients with N0-1 (n = 14) and N2b-3 disease (n = 27). One-half of deaths were observed to be the result of distant metastasis. The 5-year local control and overall survival were significantly better in patients with unilateral than in those with bilateral primary tumors. All the patients with T4b disease (n = 3) died of disease within 2 years. Conclusion: Indications for RADPLAT in patients with HPC were defined as patients with unilateral tumors staged as T3-4a and N0-1.
Rights: © 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
資料タイプ: article (author version)
URI: http://hdl.handle.net/2115/63714
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 本間 明宏

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学